Skip to main content
. Author manuscript; available in PMC: 2010 Jan 1.
Published in final edited form as: Prostate. 2009 Jan 1;69(1):92–104. doi: 10.1002/pros.20856

Figure 4.

Figure 4

DU145 xenograft growth curves (mm3) in 177Lu-hu3S193 and AG1478 Combined Modality Radioimmunotherapy study in mice receiving saline vehicle (■), 80μg hu3S193 (△), 400μg AG1478 (▼), 177Lu-hu3S193 (◇), 177Lu-huA33 (□) and 177Lu-hu3S193 + AG1478 (●) at doses of (A) 25μCi, (B) 50μCi, (C) 100μCi and (D) 200μCi radiolabeled mAb, (Mean ± SD, n = 6). Statistical significance was assessed at termination of placebo control mice on day 32 (arrow).

Kaplan-Meier survival curves in the 177Lu-hu3S193 and AG1478 Combined Modality Radioimmunotherapy study. Mice in (E) received saline vehicle (■), 80μg hu3S193 (▲) or 400μg AG1478 (▼). The survival curves for mice that received 177Lu-hu3S193 alone at doses of 25μCi (■) or 50μCi (▼) or 177Lu-hu3S193 + AG1478 at doses of 25μCi (□) or 50μCi (▽) are shown in (F). Note that higher dose groups were excluded as AG1478 did not alter survival in these groups.